SEC Form 4 · accession 0001209191-19-011174
INTEGRA LIFESCIENCES HOLDINGS CORP · IART
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert T. Davis Jr.
Officer — CVP,PRES-ORTHO & TISSUE TECH
Period of report
Feb 14, 2019
Accepted (ET)
Feb 19, 2019 · 5:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000917520
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 14, 2019 | A | 3,759 | $0.00 | A | 44,579 | D | |
| Common StockF2 | Feb 14, 2019 | A | 3,541 | $0.00 | A | 48,120 | D | |
| Common StockF3 | Feb 14, 2019 | A | 1,641 | $0.00 | A | 49,761 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 34% of the shares will vest on March 14, 2019 at 150% of target, the third anniversary of the grant date.
- F2On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 13, 2017 Performance Stock Award. Accordingly, 33% of the shares will vest on March 13, 2019 at 150% of target, the second anniversary of the grant date.
- F3On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018 under the March 13, 2018 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2019 at 89.5% of target, the first anniversary of the grant date.